TARA Protara Therapeutics, Inc.: Company Short-Term Debts

Symbol and logo of brand Protara Therapeutics (TARA)

Protara Therapeutics (TARA) is actively developing its portfolio of treatments for rare tumors and lymphatic system pathologies. Business growth is driven by TARA-002 trials, orphan drug status, and a lack of competitors in the niche. The current separate_debt_short metric stands at 0.00. The market dynamics reflected in the price action below demonstrate the financial condition of this company specializing in oncology therapies.

TARA Protara Therapeutics Inc Company Short-Term Loans and Borrowings (07/04/2022 - 10/30/2026)

TARA (Protara Tx): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Protara Therapeutics, Inc.|TARA - Consensus Target
- company stock capitalization data:
Market Capitalization Protara Therapeutics, Inc.|TARA - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Protara Therapeutics|TARA - Accounting Value of Company|Market Cap to Net Assets Ratio protaratx.com|TARA - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Protara Therapeutics|TARA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Protara Therapeutics|TARA - Company Aggregate Debts|Debt to Book Capitalization Ratio Protara Therapeutics, Inc.|TARA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Protara Therapeutics|Quick Liquidity protaratx.com
- earnings and multiples data:
TARA - Profit After Tax
Analysis of all company metrics:TARA - Protara Therapeutics, Inc.
Manufactured products of protaratx.com

For the biotech sector, Protara Therapeutics (TARA) relies on a critical balance between current liabilities and available capital. The company's short-term loans and credits reflect the total volume of payments due for settlement within the coming year. This chart allows for an assessment of the risk of cash flow gaps prior to the commercialization of rare disease therapies. Monitoring this metric confirms the issuer's ability to comply with covenants. Investors should weigh these debts against the pace of drug development.

Competing companies

BeiGene - Company Short-Term Debts|Halozyme Therapeutics, Inc. (HALO) - Company Current Liabilities|RVMD: Company Short-Term Debts|Short-Term Debt Ascentage Pharma Corp (AAPG)|Company Short-Term Debt CG Oncology, Inc.|URGN: Company Short-Term Loans and Borrowings|Company Current Liabilities BCAX (Bicara Therapeutics)|PSNL (Personalis Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debts ERAS (Erasca Corp)|DCTH - Company Current Liabilities|YMAB: Company Current Liabilities|AURA - Company Short-Term Debts|candeltx.com (CADL) - Company Short-Term Debt|Accuray Inc - Company Short-Term Loans and Borrowings|SLS (SELLAS Life Sciences Group, Inc.) - Company Short-Term Debts|Short-Term Debt Actuate Therapeutics Inc ACTU|Company Short-Term Debt Citius Oncology, Inc. (CTOR)|HURA: Current Liabilities|Company Short-Term Debt Fate Therapeutics FATE|Company Short-Term Loans and Borrowings WHWK|TCRX - Company Short-Term Debt|Short-Term Debt Champions Oncology|XBIT (xbiotech.com) - Company Current Liabilities|CVM: Amount of Current Liabilities|OSTX (OS Therapies) - Company Short-Term Debts|Company Short-Term Debts Radiopharm Theranostics Ltd|Company Short-Term Debt Artiva Biotherapeutics, Inc. (ARTV)|ANL (adlainortye.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts VERU (Veru Inc.)|Company Short-Term Debts tempesttx.com TPST|XLO: Company Current Liabilities|Company Short-Term Loans and Borrowings RENB (Renovaro Inc.)|MURA (muraloncology.com) - Company Current Liabilities|KAPA: Amount of Current Liabilities|OKUR (OnKure Therapeutics, Inc.) - Company Short-Term Debts|GDTC: Company Short-Term Loans and Borrowings|Company Short-Term Debts CRIS|APLM - Short-Term Debt|Company Short-Term Debt Tharimmune Corp THAR|Company Short-Term Loans and Borrowings ADVB|Genprex, Inc. - Company Short-Term Debts|CLDI - Company Short-Term Debts|Sunshine Biopharma (SBFM) - Company Short-Term Debt|Current Liabilities XBIO (Xenetic Biosciences, Inc.)|SLRX (Salarius) - Company Short-Term Debts|Short-Term Debt Kitov Pharma PPBT|Company Current Liabilities AONC (American Oncology Network)|Company Short-Term Debts beigene.com (BGNE)|Checkpoint Therapeutics, Inc. - Company Current Liabilities|Amount of Current Liabilities ELEV (Elevation Oncology Inc.)|iCAD Corp - Company Short-Term Debts|Short-Term Debt Volume Ikena Oncology, Inc. IKNA|NTBL: Company Short-Term Debts|Company Current Liabilities Viracta Therapeutics, Inc.|Company Short-Term Debt MorphoSys|NAYA Biosciences Inc (NAYA) - Short-Term Debt Volume|Company Current Liabilities AAPGV (Ascentage Pharma Group Ltd)